ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 2112 - appropriations legislation covering the Food and Drug Administration.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Medicare/Medicaid MMM
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Labor Issues/Antitrust/Workplace LBR
HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Pharmacy PHA
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.